Daniel Gilbert

Washington, D.C.

Reporter covering the business of medicine

Education: University of Chicago, BA in International Studies

Daniel Gilbert joined The Washington Post in 2022 and writes about the business of medicine. He previously spent seven years as an investigative reporter for the Seattle Times, and before that covered business and energy for the Wall Street Journal in Houston. As a staff writer for the Bristol Herald Courier in Bristol, Va., his reporting on Virginia’s mismanagement of natural-gas royalties received the 2010 Pulitzer Prize for Public Service.
Latest from Daniel Gilbert

How Washington allowed bank CEOs to pocket huge bonuses amid failures

Executive pay rules are getting new scrutiny after SVB’s collapse — but still they may not change.

April 23, 2023

Executive behind ChatGPT pushes for a new revolution: Psychedelics

Sam Altman is behind a start-up that aims to tap into the promise that psychedelic drugs have shown for mental health and drug disorders, and make them widely available.

April 22, 2023

Silicon Valley Bank’s risk model flashed red. So its executives changed it.

Silicon Valley Bank's rapid growth raised internal concerns that were overshadowed in a culture of executives driven to deliver profits, former employees say.

April 2, 2023

ADHD drugs such as Adderall spiked among adults in pandemic, CDC finds

Adults using prescription stimulants for attention-deficit/hyperactivity disorder sharply increased from 2020 to 2021, a government study found, the latest to highlight changes wrought by the pandemic.

March 30, 2023

An Adderall shortage has not let up. Here is why.

It puts a spotlight on virtual prescribing and supply chain issues.

March 30, 2023

The top 3 insulin makers recently announced price cuts. Here’s what to know

The drugmaker says the move will make the diabetes medication more accessible, especially for those who have trouble navigating the “complex health care system.”

March 17, 2023

Novo Nordisk becomes latest producer to slash insulin prices

Novo Nordisk said it would cut list prices of several of its insulin products by as much as 75 percent, the latest major producer to reduce prices following public pressure to curb the cost of diabetes treatment.

March 14, 2023

Pfizer seeks another ‘moonshot’ with $43 billion cancer deal

Pfizer said it will buy Seagen, a major push into cancer-fighting drugs as Pfizer remakes itself with financial windfall netted from its covid treatments.

March 13, 2023

The race to beat Elon Musk to put chips in people’s brains

Though their approaches vary, innovative companies like Paradromics and Synchron are trying to hack the brain’s instructions to the body and transmit them directly to an electronic device — enabling, for example, a person to move a cursor by thinking about it.

March 3, 2023

Eli Lilly to cut insulin prices by 70 percent

The price of the medication has become a political issue as diabetics have struggled to afford the lifesaving drug

March 1, 2023